Treatment of diabetes with vanadium salts: General overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil

Diabetes/Metabolism Research and Reviews

Volumn 17, Issue 1, 2001, Pages 55-66

  Shafrir, Eleazar ^a   Spielman, Susanna ^a   Nachliel, Idit ^a   Khamaisi, Mogher ^a   Bar On, Hanoch ^a   Ziv, Ehud ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; VANADYL SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; CYTOSOL; DIABETES MELLITUS; GERBIL; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MOLECULAR BIOLOGY; MUSCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSAMMOMYS OBESUS; RAT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET; ENERGY INTAKE; GERBILLINAE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; PHOSPHOPROTEINS; RATS; RECEPTOR, INSULIN; VANADIUM COMPOUNDS;

EID: 0035097990     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-7560(2000)9999:9999<::AID-DMRR165>3.0.CO;2-J     Document Type: Article

References (121)

1. Potential use of vanadium compounds in the treatment of diabetes mellitus
2. The role of vanadium in the management of diabetes
3. Vanadium and diabetes
4. Insulin-like effects of vanadium: Mechanisms of action, clinical and basic implications
5. Insulin-mimetic action of vanadyl complexes
6. Effects of vanadium complexes with organic ligands on glucose metabolism: A comparison study in diabetic rats
7. Increased potency of vanadium using organic ligands
8. L-Glutamic acid γ-monohydroxamate. A potentiator of vanadium-evoked glucose metabolism in vitro and in vivo
9. Oral administration of vanadate normalizes blood glucose levels in streptozotocin treated rats. Characterization and mode of action
10. Oral vanadyl sulfate in treatment of diabetes mellitus in rats
11. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats
12. Studies of vanadyl sulfate as a glucose-lowering agent in STZ-diabetic rats
13. Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats
14. Oral vanadium and lowering of blood glucose
15. Improvements of impaired glucose tolerance by oral administration of vanadyl sulfate by gavage in streptozotocin-induced diabetic rats
16. Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats
17. In vivo effects of peroxovanadium compounds in BB rats
18. Gluconeogenesis in non obese diabetic- (NOD) mice: In vivo effects of vanadate treatment on hepatic glucose-6-phosphatase and phosphoenolpyruvate carboxykinase
19. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate
20. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate
21. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus
22. Vanadate normalizes hyperglycemia and phosphoenolpyruvate carboxykinase mRNA levels in ob/ob mice
23. Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice
24. Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression
25. Oral vanadate decreases muscle insulin resistance in obese fa/fa rats
26. Effects of low and high dose administration of bis(maltolato) oxovanadium (IV) on fa/fa Zucker rats
27. Acute and chronic administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats
28. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies
29. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus
30. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects
31. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus
32. Long-term effects of vanadyl treatment on streptozocin-induced diabetes in rats
33. Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment
34. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats
35. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemia fa/fa rats
36. Long-term effectiveness of oral vanadyl sulfate in STZ rats
37. Activation by vanadate of glycolysis in hepatocytes from diabetic rats
38. Tissue-specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate
39. Insulin-like effect of vanadate on malic enzyme and glucose-6-phosphate dehydrogenase activities in streptozotocin-induced diabetic rat liver
40. Effects of vanadate on the expression of genes involved in fuel homeostasis in animal models of Type 1 and Type II diabetes
41. Vanadate induction of L-type pyruvate kinase in mRNA in adult rat hepatocytes in primary culture
42. Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats
43. Oral administration of vanadate to diabetic rats restores liver 6-phosphofructo-2-kinase content and mRNA
44. Vanadate treatment increases the activity of glycolytic enzymes and raises fructose 2,6-bisphosphate concentration in hearts from diabetic rats
45. Insulin-like effects of vanadate on rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA and protein induction in diabetic rats
46. Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms
47. Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozocin-induced diabetic rats
48. In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals
49. Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase
50. Effects of vanadium treatment on the alterations of cardiac glycogen phosphorylase and phosphorylase kinase in streptozotocin-induced chronic diabetic rats
51. Effects of oral vanadyl treatment on diabetes-induced alterations in the heart GLUT-4 transporter
52. Effects of vanadate on glucose transporter (GLUT4) intrinsic activity in skeletal muscle plasma membrane giant vesicles
53. Vanadate stimulates D-glucose transport into sarcolemmal vesicles from rat skeletal muscles
54. Effects of peroxovanadate complexes on reducing glycemia in diabetic rats and translocation of glucose transporter
55. Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide
56. Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: Effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2
57. Vanadate regulates glucose transporter (Glut-1) expression in NIH3T3 mouse fibroblasts
58. Vanadate stimulates system-A amino acid transport activity in skeletal muscle - Evidence for the involvement of intracellular-pH as a mediator of vanadate action
59. Insulin-mimetic agents vanadate and pervanadate stimulate glucose but inhibit amino acid uptake
60. Vanadate augments insulin-stimulated insulin receptor kinase activity and prolongs insulin action in rat adipocytes
61. Respiratory burst and tyrosine phosphorylation by vanadate
62. Peroxovanadate induces tyrosine phosphorylation of multiple signaling proteins in mouse liver and kidney
63. Peroxovanadate and insulin action in adipocytes from NIDDM patients. Evidence against a primary defect in tyrosine phosphorylation
64. Vanadate increases cell surface insulin binding and improves insulin sensitivity in both normal and insulin-resistant rat adipocytes
65. Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation
66. Does the insulin-mimetic action of vanadate involve insulin receptor kinase?
67. Anti-diabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity
68. Impaired insulin action but normal insulin receptor activity in diabetic rat liver: Effect of vanadate
69. Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation
70. Induction of tyrosine phosphorylation and T-cell activation by vanadate peroxide, an inhibitor of protein tyrosine phosphatases
71. The insulin mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity, nor phosphorylation in mouse diaphragm in vivo
72. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at post-insulin-receptor level
73. Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidyl inositol 3-kinase activity in adipocytes from young and old rats
74. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT4 translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C
75. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes
76. Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes
77. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation
78. Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes
79. Modulation of insulin action by vanadate: Evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling
80. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate
81. Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver
82. Inhibition of a Src homology 2 domain containing protein tyrosine phosphatase by vanadate in the primary culture of hepatocytes
83. Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: Specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(Phen)
84. Vanadyl sulphate differently influences insulin response to glucose in isolated pancreas of normal rats after in vivo or in vitro exposure
85. Long-term antidiabetic activity of vanadyl after treatment withdrawal: Restoration of insulin secretion?
86. Vanadate stimulation of insulin release in normal mouse islets
87. 4 treatment: Persistence of insulin secreting capacities assessed by isolated pancreas studies
88. Partial preservation of pancreatic beta-cells by vanadium: Evidence for long-term amelioration of diabetes
89. Islet amyloid polypeptide in Psammomys obesus (sand rat): Effects of nutritionally induced diabetes and recovery on low-energy diet or vanadyl sulfate treatment
90. Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats
91. Fructose/sucrose metabolism, its physiological and pathological implications
92. Effects of vanadate administration on the high sucrose diet-induced aberrations in normal rats
93. Effects of high sucrose diet on insulin-like effects of vanadate in diabetic rats
94. Vanadyl sulfate prevents fructose-induced hyperinsulinemia and hypertension in rats
95. Antihypertensive effects of vanadium compounds in hyperinsulinemic hypertensive rats
96. Elevated blood pressure in spontaneously hypertensive rats consuming a high sucrose diet is associated with elevated angiotensin II and is reversed by vanadium
97. Relationship between reduction in food intake and amelioration of hyperglycemia by oral vanadate in STZ-induced diabetic rats
98. Effects of chronic vanadate administration in the STZ-induced diabetic rat. The anti-hyperglycemic action of vanadate is attributable entirely to its suppression of feeding
99. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats
100. Psammomys obesus: Nutritionally induced NIDDM-like syndrome on "thrifty gene" background
101. Cellular mechanism of nutritionally induced insulin resistance: The desert rodent Psammomys obesus and other animals in which insulin resistance leads to detrimental outcome
102. Nutritionally induced insulin resistance and receptor defect leading to β-cell failure in animal models
103. Insulin resistance, beta cell survival and apoptosis in Type 2 diabetes: Animal models and human implications
104. The pathogenesis and prevention of diabetes in adults
105. The efficiency of sand rat metabolism is responsible for development of obesity and diabetes
106. Relative contribution of glycogen synthesis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats
107. Insulin resistance in the NIDDM model Psammomys obesus in the normoglycaemic, normoinsulinaemic state
108. Hyperinsulinemia induces a reversible impairment in insulin receptor function leading to diabetes in the sand rat model of non-insulin-dependent diabetes mellitus
109. Lipoic acid reduces glycemia and increases muscle GLUT4 content in streptozotocin-diabetic rats
110. Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin
111. Effects of vanadyl sulfate on glucose homeostasis in severe diabetes induced by streptozotocin in rats
112. Regulation of the insulin receptor kinase by hyperinsulinemia
113. Mechanism of insulin resistance in experimental hyperinsulinemic dogs
114. Protein kinase C mediates hyperglycemia induced insulin resistance through serine phosphorylation of IRS-1
115. Serine residues 994 and 1023/25 are important for insulin receptor kinase inhibition by protein kinase C isoforms β2 and θ
116. Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling
117. Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus
118. Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes
119. Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic versus mitogenic effects
120. Hyperglycemia-induced β-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes
121. Hydrophobic carriers of vanadyl ions augment the insulinomimetic actions of vanadyl ions in rat adipocytes